Brain, Vol. 125, No. 1, 150-158,
January 1, 2002
© 2002 Oxford University Press
Genetic basis for clinical expression in multiple sclerosis
1Department of Neurology, University of California, San Francisco, California, 2Center for Human Genetics, Department of Medicine, Duke University Medical Center, Durham, North Carolina, and 3Program in Human Genetics, Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA Correspondence to: S. L. Hauser, Department of Neurology, University of California at San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0114, USA E-mail: hauser{at}itsa.ucsf.edu
Multiple sclerosis is a clinically heterogeneous demyelinating disease and an important cause of acquired neurological disability. An underlying complex genetic susceptibility plays an important role in multiple sclerosis aetiology; however, the role of genetic factors in determining clinical features of multiple sclerosis is unknown. We studied 184 stringently ascertained Caucasian multiple sclerosis families with multiple affected cases. A detailed evaluation of patient histories identified clinical variables including age of onset, initial clinical manifestations and disease severity. The concordance within families for continuous and categorical clinical variables was investigated using an intraclass correlation or Cohen’s kappa coefficient, respectively. Genetic analyses included model-dependent, model-independent and association methodology. Linear and logistic regression models were used to evaluate the effect of human leucocyte antigen (HLA)-DR2 (DRB1*1501, DQB1*0602) on clinical outcome, taking account of correlation within families. Significant concordance for early clinical manifestations within families was observed for individuals with exclusive optic neuritis and/or spinal cord involvement as first and second multiple sclerosis attacks (P < 10–6). Linkage (LOD = 3.80, 
= 0.20) and association (P = 0.0002) to HLA-DR were present in the dataset; however, linkage was restricted to families in which the DR2 haplotype was present in at least one nuclear member. No evidence for linkage to HLA-DR in DR2-negative families was observed. When families were stratified by concordance of early clinical manifestations, a significant DR2 association was present in all subgroups. Concordance for early manifestations of multiple sclerosis was present in this familial dataset, but was not associated with HLA-DR2. The association of DR2 in families with different clinical presentations suggests that a common basis exists for susceptibility in multiple sclerosis. However, non-HLA genes or other epigenetic factors must modulate disease expression. Locus heterogeneity at the HLA region suggests a distinct immunopathogenesis in DR2 negative patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Schmidt, D. Williamson, and A. Ashley-Koch HLA-DR15 Haplotype and Multiple Sclerosis: A HuGE Review Am. J. Epidemiol., May 15, 2007; 165(10): 1097 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Hensiek, S. R. Seaman, L. F. Barcellos, A. Oturai, M. Eraksoi, E. Cocco, L. Vecsei, G. Stewart, B. Dubois, J. Bellman-Strobl, et al. Familial effects on the clinical course of multiple sclerosis Neurology, January 30, 2007; 68(5): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Love Demyelinating diseases. J. Clin. Pathol., November 1, 2006; 59(11): 1151 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Barcellos, S. Sawcer, P. P. Ramsay, S. E. Baranzini, G. Thomson, F. Briggs, B. C.A. Cree, A. B. Begovich, P. Villoslada, X. Montalban, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis Hum. Mol. Genet., September 15, 2006; 15(18): 2813 - 2824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers Neurology, May 9, 2006; 66(9): 1373 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alter, E. Kahana, N. Zilber, A. Miller, and for the Israeli MS Study Group Multiple sclerosis frequency in Israel's diverse populations Neurology, April 11, 2006; 66(7): 1061 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Traherne, L. F. Barcellos, S. J. Sawcer, A. Compston, P. P. Ramsay, S. L. Hauser, J. R. Oksenberg, and J. Trowsdale Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15 Hum. Mol. Genet., January 1, 2006; 15(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions Arch Neurol, September 1, 2005; 62(9): 1345 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A.C. Cree, O. Khan, D. Bourdette, D. S. Goodin, J. A. Cohen, R. A. Marrie, D. Glidden, B. Weinstock-Guttman, D. Reich, N. Patterson, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis Neurology, December 14, 2004; 63(11): 2039 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kheradvar, A. R. Tabassi, B. Nikbin, F. Khosravi, M. Naroueynejad, B. Moradi, and A. A. Amirzargar Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study Multiple Sclerosis, October 1, 2004; 10(5): 526 - 531. [Abstract] [PDF]
|
|
|
|
 |
|
 N. K. U. Koehler, C. P. Genain, B. Giesser, and S. L. Hauser The Human T Cell Response to Myelin Oligodendrocyte Glycoprotein: A Multiple Sclerosis Family-Based Study J. Immunol., June 1, 2002; 168(11): 5920 - 5927. [Abstract] [Full Text] [PDF]
|
|